

STRAINSFORPAINS

December 2023

Strainsforpains makes the medical cannabis decision easier; our app educates the medical specialist and dispensary, as well as the consumer, to the multiple strains that are available for specific pains or ailments. The company has also expanded its mission in incorporating the manufacturing and sale of CBD and THC products that we will manufacture at the Pennsylvania facility. as well as outsourced vendors. The Company has also entered into various joint ventures, patent sharing arrangements, and agreements with CBD liposome company's ,as well as those involved in telehealth and CBD production. The Company has a JV deal with Arizona based Cannasphere-Biotech Ltd. to co-develop and manufacture water soluble CBD products. In January 2023 we have entered into an agreement with 'Popped' to increase our CBD product line. We believe that the CBD beverage market will reach 2.8 billion in sales by 2025.

The Company App will be expanding to the iOS platform for Apple phones in the 1st Quarter of 2024. The Strainsforpains app is a user based recommendation application that scientifically helps determine which cannabis brand or strain is right for you, based upon personal data and strain genetics. The Strainsforpains tracker app, which was launched in December 2019, allows users to actively monitor and manage their personal pain from their ailments, as they are treated by medical marijuana, with over 100 ailments and 5000 brands and levels of effectiveness.

Our app helps determine which strains are most effective for you. The end users communicate advanced monitoring and management, allowing the app to track symptoms, treatments, impact, history, data and reports on all of the data collected. This allows dispensaries, growers, pharmaceutical companies, and researchers to share comprehensive reporting. Our continuous data is a key factor for the app and allows daily updates to patients and groups. We have analyzed thousands of clinical studies. The company has shown its app at the MJ Bizcon convention in Las Vegas, Nevada. The App will drive name recognition and Brand adoption within the medical/ research community and general population, generating revenue through Subscription and Advertising.

The company has announced that we have commenced talks with Columbia Care of New York City, to license our first two products for migraines and menstrual cramps medical cannabis products. The Company's upcoming Branded product line will include 5-6 symptom specific Strains formulations. with possibility of a dozen more, including Arthritis, Depression, Autism, Insomnia, Gastrointestinal , Anxiety, PTSD , and Musco-Skeletal pain. We will also create a high quality pure grade CBD to be sold in 50 States, and a high % THC product in the 39 Medicinal States in the forms of tinctures, gummies and balms. In the 4th quarter 2023 we have achieved \$65,000 in orders from our first CBD branded products.

The Company medical advisor, Dr. Michael Stern, is well known for his diet book, 'Dr. Michael Stern's Rotation Diet', and we will showcase many of his suggestions with the end user giving feedback as to their results. The company is publicly traded on the OTC market under the symbol "EBYH". The company achieved positive revenues in fiscal 2020.



“Our app will assist pain management professionals & dispensaries in making better choices for the consumer”

***Y. Simon Shainberg
CEO***

Latest Info

Strainsforpains collaborating and sharing data with Mount Sinai Hospital physicians on pain management education. Data base considered to be up to 50,000 doctors. Strainsforpains collaborating with University of Vermont and SUNY on company data. Company management to attend several medical cannabis shows in 2024. Management will speak and present at certain events.

While the majority of States in the US continue to impose a total ban on cannabis, there are 38 states which allow its use for medical purposes, and according to the developers of this app the prohibition on medical cannabis "rapidly coming to a close". The global telehealth market is projected to reach \$55 billion in 2025 from \$25 billion in 2020, at a CAGR of 17%. We feel within next 36 months the USA will adopt legal cannabis for medical use as well as nutritional uses.


Strainsforpains has collaborated with major research facilities, like University of Vermont and New York Mount Sinai to further develop existing data sources and marketing. Company management has associated with State University of New York(SUNY) in residencies related to cannabis education. The Company has entered into its public company stage and has brought on board industry experts as consultants. We will leverage our Public Company status through the Capital markets and collaborations ; future Price appreciation

Our Licensing and JV opportunities could supply perpetual revenues built over time. There are thousands of Strains with countless benefits to people. with multiple sources that can become a major source of revenues over time. Our company has also initiated 'focus groups' to help us better target audiences, consumers, medical professionals, industry players, and third party service providers. We feel that our cutting edge technology will be instrumental in the help of veterans who suffer from many diseases including PTSD. Our company is committed in the fight against opioids, and look to prevent many thousands of deaths occurring on an annual basis in the US alone. We will also participate in telehealth platforms that provide large players in the industry access to our findings. As the foundational business is steadily progressing, we see huge potential with CBD Nutrition and CBD for Pets.

Our research and data has resulted in an app, with hundreds of different strains available, each of which contains a combination of several cannabinoids of varying strengths. The complexity is increased when you consider that each strain reacts differently with your own unique combination of cannabinoid receptors to produce medical, psychological, and recreational effects on the human body.

Long-term rental income from our Pennsylvania facility will also house our Manufacturing base. We will retrofit our Pennsylvania facility to manufacture and sell CBD products, extracted from hemp. The 2021 CBD market was \$1.6 billion, and can grow to \$17 billion by 2025. The estimate of growth is 32% CAGR. The most growth will be seen in the health and wellness category, like nutraceuticals (\$6 billion) and topicals (\$4 billion).

U.S. Cannabis Industry Total Economic Impact: 2021-26



Source: MJBizFactbook
© 2022 MJBiz, a division of Emerald X, LLC

NOTE: Estimates are high end of scale.

Contact Us

Company address is
385 Grand Street
Suite 806,
New York, N.Y. 10002

Company phone number is
646-481-4161

Email:
Strainsforpains@gmail.com

Website:
strainsforpains.com

U.S. Cannabis Retail Sales Estimates: 2015-26




Source: MJBiz Factbook

© 2022 MJBiz, a division of Emerald X, LLC

U.S. Cannabidiol Market

size, by sale type, 2020 - 2030 (USD Billion)




14.9%

U.S. Market CAGR,
2022 - 2030


Source:
www.grandviewresearch.com

Current CBD Users' Preferred Purchasing Channels



Source: High Yield Insights

Copyright 2019 Marijuana Business Daily, a division of Anne Holland Ventures Inc. All rights reserved.



Potential Therapeutic Uses of Medical Marijuana

Advisors

Dr. Michael Stern graduated from medical school in 1973 and since 1983 has been a board-certified urologist and urologic surgeon. Dr. Stern served as an adjunct clinical faculty member at Bastyr University School of Naturopathic Medicine for 11 years (1995 -- 2006). Dr. Stern operates the Northwest Healthy Options Clinic in Seattle, Washington. Dr. Stern continues advising patients on lifestyle issues and alternative healthy treatments for a wide variety of diseases, including medical cannabis.

Dr. Bindiya Moorjani was awarded a Ph.D. in biomedical sciences from the Fishberg Research Center for Neurobiology, Mount Sinai School of Medicine, New York University. She has authored scientific studies.

Samuel Epstein, is a certified petroleum geologist and President of Geoval Consulting LLC, a firm that applies geological expertise to evaluate prime target investment opportunities. He has authored over 40 publications in scientific journals, with the focus on successfully merging geology and economic viability. For over 30 years was an investment advisor as an SVP for Merrill Lynch and Morgan Stanley. He serves on the Board of Governors for Touro College and University. He is also an executive director of the Touro College Center for Environmental and Geological research.

Management

Yehoshua Shainberg, CEO, brings over four decades of business experience in finance, strategy, marketing, technology, and development. He has spent 17 years researching clinical studies and developing the database. Mr. Shainberg is a member of the prestigious International Cannabinoid Research Society (ICRS), consisting of leading professionals in their field.